Global Checkpoint Inhibitors for Treating Cancer Market Growth 2026-2032
The global Checkpoint Inhibitors for Treating Cancer market size is predicted to grow from US$ 62486 million in 2025 to US$ 102461 million in 2032; it is expected to grow at a CAGR of 7.9% from 2026 to 2032.
Checkpoint inhibitors for treating cancer are immuno-oncology medicines that block inhibitory immune-regulatory pathways, principally PD-1, PD-L1, CTLA-4 and LAG-3, allowing activated T cells to retain or recover their ability to identify and attack malignant cells. Checkpoint inhibitors includes commercial monoclonal antibodies, bispecific antibodies, single-domain antibody fusion products, fixed-dose antibody combinations and antibody-enzyme coformulations approved for cancer treatment.
Upstream of checkpoint inhibitors include mammalian cell lines, cell-culture media, single-use bioreactor assemblies, chromatography resins, filtration membranes, sterile excipients, glass vials, prefilled delivery components and cold-chain packaging. Manufacturing requires validated biologic production systems, aseptic fill-finish capacity, regulatory-grade analytical testing and continuous comparability control. Downstream customers consist primarily of oncology hospitals, specialist cancer centers, infusion clinics, public health systems, private insurers, government reimbursement agencies and national or regional pharmaceutical procurement platforms. Purchasing normally occurs through hospital formulary inclusion, national reimbursement negotiation, annual tendering, group purchasing contracts and long-term supply agreements. A representative producer gross margin is estimated at 79.0%, supported by biologic manufacturing barriers, regulatory exclusivity, extensive clinical evidence, broad approved labels, established physician familiarity and the high cost of switching treatment protocols.
In the current market, global production of Checkpoint inhibitors is around 27.5 million Units, with an average selling price of about 2,315 USD per Unit. Top 5 suppliers control approximately 91 percent of global revenue CR5. Merck leads through Keytruda and its subcutaneous formulation, followed by Bristol Myers Squibb with the Opdivo, Yervoy and Opdualag franchise. AstraZeneca, Roche and Regeneron form the remainder of the top five. North America remains the largest revenue market because of high net treatment prices and broad use in earlier treatment settings. Europe is the second-largest revenue region, while China has a substantially higher share of treatment volume than revenue because domestic PD-1, PD-L1 and bispecific products are sold at lower net prices following reimbursement negotiation. Japan is also material through Ono Pharmaceutical?s Opdivo franchise.
From 2026 through 2032, treatment volume is expected to increase faster than revenue as checkpoint therapy moves further into neoadjuvant, adjuvant and maintenance settings while average prices decline. Subcutaneous versions of established antibodies should reduce infusion-chair time and hospital administration costs, but they will also intensify life-cycle competition among incumbent suppliers. Chinese producers are expected to expand beyond the domestic market through international approvals, licensing agreements and lower-cost supply, particularly in lung, gastric, esophageal and hepatobiliary cancers. Bispecific products combining PD-1 with CTLA-4, VEGF or other immune pathways will increase their share, although only products demonstrating clear survival or safety advantages are likely to achieve broad reimbursement. Patent expiry around leading PD-1 franchises, biosimilar development, national price negotiation and payer restrictions will place sustained pressure on ASP. Competition will also come from antibody-drug conjugates, targeted therapies, radioligand treatments and biomarker-selected combination regimens.
LP Information, Inc. (LPI) ' newest research report, the ?Checkpoint Inhibitors for Treating Cancer Industry Forecast? looks at past sales and reviews total world Checkpoint Inhibitors for Treating Cancer sales in 2025, providing a comprehensive analysis by region and market sector of projected Checkpoint Inhibitors for Treating Cancer sales for 2026 through 2032. With Checkpoint Inhibitors for Treating Cancer sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Checkpoint Inhibitors for Treating Cancer industry.
This Insight Report provides a comprehensive analysis of the global Checkpoint Inhibitors for Treating Cancer landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Checkpoint Inhibitors for Treating Cancer portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Checkpoint Inhibitors for Treating Cancer market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Checkpoint Inhibitors for Treating Cancer and breaks down the forecast by Checkpoint Target, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Checkpoint Inhibitors for Treating Cancer.
This report presents a comprehensive overview, market shares, and growth opportunities of Checkpoint Inhibitors for Treating Cancer market by product type, application, key manufacturers and key regions and countries.
Segmentation by Checkpoint Target:
What is the 10-year outlook for the global Checkpoint Inhibitors for Treating Cancer market?
What factors are driving Checkpoint Inhibitors for Treating Cancer market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Checkpoint Inhibitors for Treating Cancer market opportunities vary by end market size?
How does Checkpoint Inhibitors for Treating Cancer break out by Checkpoint Target, by Application?
Checkpoint inhibitors for treating cancer are immuno-oncology medicines that block inhibitory immune-regulatory pathways, principally PD-1, PD-L1, CTLA-4 and LAG-3, allowing activated T cells to retain or recover their ability to identify and attack malignant cells. Checkpoint inhibitors includes commercial monoclonal antibodies, bispecific antibodies, single-domain antibody fusion products, fixed-dose antibody combinations and antibody-enzyme coformulations approved for cancer treatment.
Upstream of checkpoint inhibitors include mammalian cell lines, cell-culture media, single-use bioreactor assemblies, chromatography resins, filtration membranes, sterile excipients, glass vials, prefilled delivery components and cold-chain packaging. Manufacturing requires validated biologic production systems, aseptic fill-finish capacity, regulatory-grade analytical testing and continuous comparability control. Downstream customers consist primarily of oncology hospitals, specialist cancer centers, infusion clinics, public health systems, private insurers, government reimbursement agencies and national or regional pharmaceutical procurement platforms. Purchasing normally occurs through hospital formulary inclusion, national reimbursement negotiation, annual tendering, group purchasing contracts and long-term supply agreements. A representative producer gross margin is estimated at 79.0%, supported by biologic manufacturing barriers, regulatory exclusivity, extensive clinical evidence, broad approved labels, established physician familiarity and the high cost of switching treatment protocols.
In the current market, global production of Checkpoint inhibitors is around 27.5 million Units, with an average selling price of about 2,315 USD per Unit. Top 5 suppliers control approximately 91 percent of global revenue CR5. Merck leads through Keytruda and its subcutaneous formulation, followed by Bristol Myers Squibb with the Opdivo, Yervoy and Opdualag franchise. AstraZeneca, Roche and Regeneron form the remainder of the top five. North America remains the largest revenue market because of high net treatment prices and broad use in earlier treatment settings. Europe is the second-largest revenue region, while China has a substantially higher share of treatment volume than revenue because domestic PD-1, PD-L1 and bispecific products are sold at lower net prices following reimbursement negotiation. Japan is also material through Ono Pharmaceutical?s Opdivo franchise.
From 2026 through 2032, treatment volume is expected to increase faster than revenue as checkpoint therapy moves further into neoadjuvant, adjuvant and maintenance settings while average prices decline. Subcutaneous versions of established antibodies should reduce infusion-chair time and hospital administration costs, but they will also intensify life-cycle competition among incumbent suppliers. Chinese producers are expected to expand beyond the domestic market through international approvals, licensing agreements and lower-cost supply, particularly in lung, gastric, esophageal and hepatobiliary cancers. Bispecific products combining PD-1 with CTLA-4, VEGF or other immune pathways will increase their share, although only products demonstrating clear survival or safety advantages are likely to achieve broad reimbursement. Patent expiry around leading PD-1 franchises, biosimilar development, national price negotiation and payer restrictions will place sustained pressure on ASP. Competition will also come from antibody-drug conjugates, targeted therapies, radioligand treatments and biomarker-selected combination regimens.
LP Information, Inc. (LPI) ' newest research report, the ?Checkpoint Inhibitors for Treating Cancer Industry Forecast? looks at past sales and reviews total world Checkpoint Inhibitors for Treating Cancer sales in 2025, providing a comprehensive analysis by region and market sector of projected Checkpoint Inhibitors for Treating Cancer sales for 2026 through 2032. With Checkpoint Inhibitors for Treating Cancer sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Checkpoint Inhibitors for Treating Cancer industry.
This Insight Report provides a comprehensive analysis of the global Checkpoint Inhibitors for Treating Cancer landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Checkpoint Inhibitors for Treating Cancer portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Checkpoint Inhibitors for Treating Cancer market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Checkpoint Inhibitors for Treating Cancer and breaks down the forecast by Checkpoint Target, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Checkpoint Inhibitors for Treating Cancer.
This report presents a comprehensive overview, market shares, and growth opportunities of Checkpoint Inhibitors for Treating Cancer market by product type, application, key manufacturers and key regions and countries.
Segmentation by Checkpoint Target:
- PD-1 Single-target Inhibitor
- PD-L1 Single-target Inhibitor
- CTLA-4 Single-target Inhibitor
- PD-1/LAG-3 Combination
- PD-1/CTLA-4 Dual Product
- Other Checkpoint-containing Product
- Monoclonal Antibody
- Bispecific Antibody
- Fixed-dose Antibody Combination
- Antibody Enzyme Combination
- Intravenous Liquid Concentrate
- Intravenous Lyophilized Powder
- Subcutaneous Ready-to-use Injection
- Lung Cancer
- Gastrointestinal Cancer
- Genitourinary Cancer
- Hepatobiliary Cancer
- Gynecologic Cancer
- Skin Cancer
- Breast Cancer
- Head and Neck Cancer
- Hematologic Malignancy
- Other Solid Tumors
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Merck & Co.
- Bristol Myers Squibb
- AstraZeneca
- Roche
- Regeneron Pharmaceuticals
- GSK
- Ono Pharmaceutical
- BeOne Medicines
- Merck KGaA
- Innovent Biologics
- Jiangsu Hengrui Pharmaceuticals
- Shanghai Junshi Biosciences
- Akeso
- Shanghai Henlius Biotech
- Incyte
- Sino Biopharmaceutical
- BIOCAD
- Alphamab Oncology
What is the 10-year outlook for the global Checkpoint Inhibitors for Treating Cancer market?
What factors are driving Checkpoint Inhibitors for Treating Cancer market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Checkpoint Inhibitors for Treating Cancer market opportunities vary by end market size?
How does Checkpoint Inhibitors for Treating Cancer break out by Checkpoint Target, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Checkpoint Inhibitors for Treating Cancer Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Checkpoint Inhibitors for Treating Cancer by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Checkpoint Inhibitors for Treating Cancer by Country/Region, 2021, 2025 & 2032
2.2 Checkpoint Inhibitors for Treating Cancer Segment by Checkpoint Target
2.2.1 PD-1 Single-target Inhibitor
2.2.2 PD-L1 Single-target Inhibitor
2.2.3 CTLA-4 Single-target Inhibitor
2.2.4 PD-1/LAG-3 Combination
2.2.5 PD-1/CTLA-4 Dual Product
2.2.6 Other Checkpoint-containing Product
2.2.7 Checkpoint Inhibitors for Treating Cancer Sales by Checkpoint Target
2.2.7.1 Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Checkpoint Target (2021-2026)
2.2.7.2 Global Checkpoint Inhibitors for Treating Cancer Revenue and Market Share by Checkpoint Target (2021-2026)
2.2.7.3 Global Checkpoint Inhibitors for Treating Cancer Sale Price by Checkpoint Target (2021-2026)
2.3 Checkpoint Inhibitors for Treating Cancer Segment by Molecular Format
2.3.1 Monoclonal Antibody
2.3.2 Bispecific Antibody
2.3.3 Fixed-dose Antibody Combination
2.3.4 Antibody Enzyme Combination
2.3.5 Checkpoint Inhibitors for Treating Cancer Sales by Molecular Format
2.3.5.1 Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Molecular Format (2021-2026)
2.3.5.2 Global Checkpoint Inhibitors for Treating Cancer Revenue and Market Share by Molecular Format (2021-2026)
2.3.5.3 Global Checkpoint Inhibitors for Treating Cancer Sale Price by Molecular Format (2021-2026)
2.4 Checkpoint Inhibitors for Treating Cancer Segment by Dosage Form
2.4.1 Intravenous Liquid Concentrate
2.4.2 Intravenous Lyophilized Powder
2.4.3 Subcutaneous Ready-to-use Injection
2.4.4 Checkpoint Inhibitors for Treating Cancer Sales by Dosage Form
2.4.4.1 Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Dosage Form (2021-2026)
2.4.4.2 Global Checkpoint Inhibitors for Treating Cancer Revenue and Market Share by Dosage Form (2021-2026)
2.4.4.3 Global Checkpoint Inhibitors for Treating Cancer Sale Price by Dosage Form (2021-2026)
2.5 Checkpoint Inhibitors for Treating Cancer Segment by Application
2.5.1 Lung Cancer
2.5.2 Gastrointestinal Cancer
2.5.3 Genitourinary Cancer
2.5.4 Hepatobiliary Cancer
2.5.5 Gynecologic Cancer
2.5.6 Skin Cancer
2.5.7 Breast Cancer
2.5.8 Head and Neck Cancer
2.5.9 Hematologic Malignancy
2.5.10 Checkpoint Inhibitors for Treating Cancer Sales by Application
2.5.10.1 Global Checkpoint Inhibitors for Treating Cancer Sale Market Share by Application (2021-2026)
2.5.10.2 Global Checkpoint Inhibitors for Treating Cancer Revenue and Market Share by Application (2021-2026)
2.5.10.3 Global Checkpoint Inhibitors for Treating Cancer Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Checkpoint Inhibitors for Treating Cancer Breakdown Data by Company
3.1.1 Global Checkpoint Inhibitors for Treating Cancer Annual Sales by Company (2021-2026)
3.1.2 Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Company (2021-2026)
3.2 Global Checkpoint Inhibitors for Treating Cancer Annual Revenue by Company (2021-2026)
3.2.1 Global Checkpoint Inhibitors for Treating Cancer Revenue by Company (2021-2026)
3.2.2 Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Company (2021-2026)
3.3 Global Checkpoint Inhibitors for Treating Cancer Sale Price by Company
3.4 Key Manufacturers Checkpoint Inhibitors for Treating Cancer Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Checkpoint Inhibitors for Treating Cancer Product Location Distribution
3.4.2 Players Checkpoint Inhibitors for Treating Cancer Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR CHECKPOINT INHIBITORS FOR TREATING CANCER BY GEOGRAPHIC REGION
4.1 World Historic Checkpoint Inhibitors for Treating Cancer Market Size by Geographic Region (2021-2026)
4.1.1 Global Checkpoint Inhibitors for Treating Cancer Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Checkpoint Inhibitors for Treating Cancer Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Checkpoint Inhibitors for Treating Cancer Market Size by Country/Region (2021-2026)
4.2.1 Global Checkpoint Inhibitors for Treating Cancer Annual Sales by Country/Region (2021-2026)
4.2.2 Global Checkpoint Inhibitors for Treating Cancer Annual Revenue by Country/Region (2021-2026)
4.3 Americas Checkpoint Inhibitors for Treating Cancer Sales Growth
4.4 APAC Checkpoint Inhibitors for Treating Cancer Sales Growth
4.5 Europe Checkpoint Inhibitors for Treating Cancer Sales Growth
4.6 Middle East & Africa Checkpoint Inhibitors for Treating Cancer Sales Growth
5 AMERICAS
5.1 Americas Checkpoint Inhibitors for Treating Cancer Sales by Country
5.1.1 Americas Checkpoint Inhibitors for Treating Cancer Sales by Country (2021-2026)
5.1.2 Americas Checkpoint Inhibitors for Treating Cancer Revenue by Country (2021-2026)
5.2 Americas Checkpoint Inhibitors for Treating Cancer Sales by Checkpoint Target (2021-2026)
5.3 Americas Checkpoint Inhibitors for Treating Cancer Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Checkpoint Inhibitors for Treating Cancer Sales by Region
6.1.1 APAC Checkpoint Inhibitors for Treating Cancer Sales by Region (2021-2026)
6.1.2 APAC Checkpoint Inhibitors for Treating Cancer Revenue by Region (2021-2026)
6.2 APAC Checkpoint Inhibitors for Treating Cancer Sales by Checkpoint Target (2021-2026)
6.3 APAC Checkpoint Inhibitors for Treating Cancer Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Checkpoint Inhibitors for Treating Cancer by Country
7.1.1 Europe Checkpoint Inhibitors for Treating Cancer Sales by Country (2021-2026)
7.1.2 Europe Checkpoint Inhibitors for Treating Cancer Revenue by Country (2021-2026)
7.2 Europe Checkpoint Inhibitors for Treating Cancer Sales by Checkpoint Target (2021-2026)
7.3 Europe Checkpoint Inhibitors for Treating Cancer Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Checkpoint Inhibitors for Treating Cancer by Country
8.1.1 Middle East & Africa Checkpoint Inhibitors for Treating Cancer Sales by Country (2021-2026)
8.1.2 Middle East & Africa Checkpoint Inhibitors for Treating Cancer Revenue by Country (2021-2026)
8.2 Middle East & Africa Checkpoint Inhibitors for Treating Cancer Sales by Checkpoint Target (2021-2026)
8.3 Middle East & Africa Checkpoint Inhibitors for Treating Cancer Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Checkpoint Inhibitors for Treating Cancer
10.3 Manufacturing Process Analysis of Checkpoint Inhibitors for Treating Cancer
10.4 Industry Chain Structure of Checkpoint Inhibitors for Treating Cancer
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Checkpoint Inhibitors for Treating Cancer Distributors
11.3 Checkpoint Inhibitors for Treating Cancer Customer
12 WORLD FORECAST REVIEW FOR CHECKPOINT INHIBITORS FOR TREATING CANCER BY GEOGRAPHIC REGION
12.1 Global Checkpoint Inhibitors for Treating Cancer Market Size Forecast by Region
12.1.1 Global Checkpoint Inhibitors for Treating Cancer Forecast by Region (2027-2032)
12.1.2 Global Checkpoint Inhibitors for Treating Cancer Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Checkpoint Inhibitors for Treating Cancer Forecast by Checkpoint Target (2027-2032)
12.7 Global Checkpoint Inhibitors for Treating Cancer Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Merck & Co.
13.1.1 Merck & Co. Company Information
13.1.2 Merck & Co. Checkpoint Inhibitors for Treating Cancer Product Portfolios and Specifications
13.1.3 Merck & Co. Checkpoint Inhibitors for Treating Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Merck & Co. Main Business Overview
13.1.5 Merck & Co. Latest Developments
13.2 Bristol Myers Squibb
13.2.1 Bristol Myers Squibb Company Information
13.2.2 Bristol Myers Squibb Checkpoint Inhibitors for Treating Cancer Product Portfolios and Specifications
13.2.3 Bristol Myers Squibb Checkpoint Inhibitors for Treating Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Bristol Myers Squibb Main Business Overview
13.2.5 Bristol Myers Squibb Latest Developments
13.3 AstraZeneca
13.3.1 AstraZeneca Company Information
13.3.2 AstraZeneca Checkpoint Inhibitors for Treating Cancer Product Portfolios and Specifications
13.3.3 AstraZeneca Checkpoint Inhibitors for Treating Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 AstraZeneca Main Business Overview
13.3.5 AstraZeneca Latest Developments
13.4 Roche
13.4.1 Roche Company Information
13.4.2 Roche Checkpoint Inhibitors for Treating Cancer Product Portfolios and Specifications
13.4.3 Roche Checkpoint Inhibitors for Treating Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Roche Main Business Overview
13.4.5 Roche Latest Developments
13.5 Regeneron Pharmaceuticals
13.5.1 Regeneron Pharmaceuticals Company Information
13.5.2 Regeneron Pharmaceuticals Checkpoint Inhibitors for Treating Cancer Product Portfolios and Specifications
13.5.3 Regeneron Pharmaceuticals Checkpoint Inhibitors for Treating Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Regeneron Pharmaceuticals Main Business Overview
13.5.5 Regeneron Pharmaceuticals Latest Developments
13.6 GSK
13.6.1 GSK Company Information
13.6.2 GSK Checkpoint Inhibitors for Treating Cancer Product Portfolios and Specifications
13.6.3 GSK Checkpoint Inhibitors for Treating Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 GSK Main Business Overview
13.6.5 GSK Latest Developments
13.7 Ono Pharmaceutical
13.7.1 Ono Pharmaceutical Company Information
13.7.2 Ono Pharmaceutical Checkpoint Inhibitors for Treating Cancer Product Portfolios and Specifications
13.7.3 Ono Pharmaceutical Checkpoint Inhibitors for Treating Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Ono Pharmaceutical Main Business Overview
13.7.5 Ono Pharmaceutical Latest Developments
13.8 BeOne Medicines
13.8.1 BeOne Medicines Company Information
13.8.2 BeOne Medicines Checkpoint Inhibitors for Treating Cancer Product Portfolios and Specifications
13.8.3 BeOne Medicines Checkpoint Inhibitors for Treating Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 BeOne Medicines Main Business Overview
13.8.5 BeOne Medicines Latest Developments
13.9 Merck KGaA
13.9.1 Merck KGaA Company Information
13.9.2 Merck KGaA Checkpoint Inhibitors for Treating Cancer Product Portfolios and Specifications
13.9.3 Merck KGaA Checkpoint Inhibitors for Treating Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Merck KGaA Main Business Overview
13.9.5 Merck KGaA Latest Developments
13.10 Innovent Biologics
13.10.1 Innovent Biologics Company Information
13.10.2 Innovent Biologics Checkpoint Inhibitors for Treating Cancer Product Portfolios and Specifications
13.10.3 Innovent Biologics Checkpoint Inhibitors for Treating Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Innovent Biologics Main Business Overview
13.10.5 Innovent Biologics Latest Developments
13.11 Jiangsu Hengrui Pharmaceuticals
13.11.1 Jiangsu Hengrui Pharmaceuticals Company Information
13.11.2 Jiangsu Hengrui Pharmaceuticals Checkpoint Inhibitors for Treating Cancer Product Portfolios and Specifications
13.11.3 Jiangsu Hengrui Pharmaceuticals Checkpoint Inhibitors for Treating Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 Jiangsu Hengrui Pharmaceuticals Main Business Overview
13.11.5 Jiangsu Hengrui Pharmaceuticals Latest Developments
13.12 Shanghai Junshi Biosciences
13.12.1 Shanghai Junshi Biosciences Company Information
13.12.2 Shanghai Junshi Biosciences Checkpoint Inhibitors for Treating Cancer Product Portfolios and Specifications
13.12.3 Shanghai Junshi Biosciences Checkpoint Inhibitors for Treating Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 Shanghai Junshi Biosciences Main Business Overview
13.12.5 Shanghai Junshi Biosciences Latest Developments
13.13 Akeso
13.13.1 Akeso Company Information
13.13.2 Akeso Checkpoint Inhibitors for Treating Cancer Product Portfolios and Specifications
13.13.3 Akeso Checkpoint Inhibitors for Treating Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
13.13.4 Akeso Main Business Overview
13.13.5 Akeso Latest Developments
13.14 Shanghai Henlius Biotech
13.14.1 Shanghai Henlius Biotech Company Information
13.14.2 Shanghai Henlius Biotech Checkpoint Inhibitors for Treating Cancer Product Portfolios and Specifications
13.14.3 Shanghai Henlius Biotech Checkpoint Inhibitors for Treating Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
13.14.4 Shanghai Henlius Biotech Main Business Overview
13.14.5 Shanghai Henlius Biotech Latest Developments
13.15 Incyte
13.15.1 Incyte Company Information
13.15.2 Incyte Checkpoint Inhibitors for Treating Cancer Product Portfolios and Specifications
13.15.3 Incyte Checkpoint Inhibitors for Treating Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
13.15.4 Incyte Main Business Overview
13.15.5 Incyte Latest Developments
13.16 Sino Biopharmaceutical
13.16.1 Sino Biopharmaceutical Company Information
13.16.2 Sino Biopharmaceutical Checkpoint Inhibitors for Treating Cancer Product Portfolios and Specifications
13.16.3 Sino Biopharmaceutical Checkpoint Inhibitors for Treating Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
13.16.4 Sino Biopharmaceutical Main Business Overview
13.16.5 Sino Biopharmaceutical Latest Developments
13.17 BIOCAD
13.17.1 BIOCAD Company Information
13.17.2 BIOCAD Checkpoint Inhibitors for Treating Cancer Product Portfolios and Specifications
13.17.3 BIOCAD Checkpoint Inhibitors for Treating Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
13.17.4 BIOCAD Main Business Overview
13.17.5 BIOCAD Latest Developments
13.18 Alphamab Oncology
13.18.1 Alphamab Oncology Company Information
13.18.2 Alphamab Oncology Checkpoint Inhibitors for Treating Cancer Product Portfolios and Specifications
13.18.3 Alphamab Oncology Checkpoint Inhibitors for Treating Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
13.18.4 Alphamab Oncology Main Business Overview
13.18.5 Alphamab Oncology Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Checkpoint Inhibitors for Treating Cancer Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Checkpoint Inhibitors for Treating Cancer by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Checkpoint Inhibitors for Treating Cancer by Country/Region, 2021, 2025 & 2032
2.2 Checkpoint Inhibitors for Treating Cancer Segment by Checkpoint Target
2.2.1 PD-1 Single-target Inhibitor
2.2.2 PD-L1 Single-target Inhibitor
2.2.3 CTLA-4 Single-target Inhibitor
2.2.4 PD-1/LAG-3 Combination
2.2.5 PD-1/CTLA-4 Dual Product
2.2.6 Other Checkpoint-containing Product
2.2.7 Checkpoint Inhibitors for Treating Cancer Sales by Checkpoint Target
2.2.7.1 Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Checkpoint Target (2021-2026)
2.2.7.2 Global Checkpoint Inhibitors for Treating Cancer Revenue and Market Share by Checkpoint Target (2021-2026)
2.2.7.3 Global Checkpoint Inhibitors for Treating Cancer Sale Price by Checkpoint Target (2021-2026)
2.3 Checkpoint Inhibitors for Treating Cancer Segment by Molecular Format
2.3.1 Monoclonal Antibody
2.3.2 Bispecific Antibody
2.3.3 Fixed-dose Antibody Combination
2.3.4 Antibody Enzyme Combination
2.3.5 Checkpoint Inhibitors for Treating Cancer Sales by Molecular Format
2.3.5.1 Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Molecular Format (2021-2026)
2.3.5.2 Global Checkpoint Inhibitors for Treating Cancer Revenue and Market Share by Molecular Format (2021-2026)
2.3.5.3 Global Checkpoint Inhibitors for Treating Cancer Sale Price by Molecular Format (2021-2026)
2.4 Checkpoint Inhibitors for Treating Cancer Segment by Dosage Form
2.4.1 Intravenous Liquid Concentrate
2.4.2 Intravenous Lyophilized Powder
2.4.3 Subcutaneous Ready-to-use Injection
2.4.4 Checkpoint Inhibitors for Treating Cancer Sales by Dosage Form
2.4.4.1 Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Dosage Form (2021-2026)
2.4.4.2 Global Checkpoint Inhibitors for Treating Cancer Revenue and Market Share by Dosage Form (2021-2026)
2.4.4.3 Global Checkpoint Inhibitors for Treating Cancer Sale Price by Dosage Form (2021-2026)
2.5 Checkpoint Inhibitors for Treating Cancer Segment by Application
2.5.1 Lung Cancer
2.5.2 Gastrointestinal Cancer
2.5.3 Genitourinary Cancer
2.5.4 Hepatobiliary Cancer
2.5.5 Gynecologic Cancer
2.5.6 Skin Cancer
2.5.7 Breast Cancer
2.5.8 Head and Neck Cancer
2.5.9 Hematologic Malignancy
2.5.10 Checkpoint Inhibitors for Treating Cancer Sales by Application
2.5.10.1 Global Checkpoint Inhibitors for Treating Cancer Sale Market Share by Application (2021-2026)
2.5.10.2 Global Checkpoint Inhibitors for Treating Cancer Revenue and Market Share by Application (2021-2026)
2.5.10.3 Global Checkpoint Inhibitors for Treating Cancer Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Checkpoint Inhibitors for Treating Cancer Breakdown Data by Company
3.1.1 Global Checkpoint Inhibitors for Treating Cancer Annual Sales by Company (2021-2026)
3.1.2 Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Company (2021-2026)
3.2 Global Checkpoint Inhibitors for Treating Cancer Annual Revenue by Company (2021-2026)
3.2.1 Global Checkpoint Inhibitors for Treating Cancer Revenue by Company (2021-2026)
3.2.2 Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Company (2021-2026)
3.3 Global Checkpoint Inhibitors for Treating Cancer Sale Price by Company
3.4 Key Manufacturers Checkpoint Inhibitors for Treating Cancer Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Checkpoint Inhibitors for Treating Cancer Product Location Distribution
3.4.2 Players Checkpoint Inhibitors for Treating Cancer Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR CHECKPOINT INHIBITORS FOR TREATING CANCER BY GEOGRAPHIC REGION
4.1 World Historic Checkpoint Inhibitors for Treating Cancer Market Size by Geographic Region (2021-2026)
4.1.1 Global Checkpoint Inhibitors for Treating Cancer Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Checkpoint Inhibitors for Treating Cancer Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Checkpoint Inhibitors for Treating Cancer Market Size by Country/Region (2021-2026)
4.2.1 Global Checkpoint Inhibitors for Treating Cancer Annual Sales by Country/Region (2021-2026)
4.2.2 Global Checkpoint Inhibitors for Treating Cancer Annual Revenue by Country/Region (2021-2026)
4.3 Americas Checkpoint Inhibitors for Treating Cancer Sales Growth
4.4 APAC Checkpoint Inhibitors for Treating Cancer Sales Growth
4.5 Europe Checkpoint Inhibitors for Treating Cancer Sales Growth
4.6 Middle East & Africa Checkpoint Inhibitors for Treating Cancer Sales Growth
5 AMERICAS
5.1 Americas Checkpoint Inhibitors for Treating Cancer Sales by Country
5.1.1 Americas Checkpoint Inhibitors for Treating Cancer Sales by Country (2021-2026)
5.1.2 Americas Checkpoint Inhibitors for Treating Cancer Revenue by Country (2021-2026)
5.2 Americas Checkpoint Inhibitors for Treating Cancer Sales by Checkpoint Target (2021-2026)
5.3 Americas Checkpoint Inhibitors for Treating Cancer Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Checkpoint Inhibitors for Treating Cancer Sales by Region
6.1.1 APAC Checkpoint Inhibitors for Treating Cancer Sales by Region (2021-2026)
6.1.2 APAC Checkpoint Inhibitors for Treating Cancer Revenue by Region (2021-2026)
6.2 APAC Checkpoint Inhibitors for Treating Cancer Sales by Checkpoint Target (2021-2026)
6.3 APAC Checkpoint Inhibitors for Treating Cancer Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Checkpoint Inhibitors for Treating Cancer by Country
7.1.1 Europe Checkpoint Inhibitors for Treating Cancer Sales by Country (2021-2026)
7.1.2 Europe Checkpoint Inhibitors for Treating Cancer Revenue by Country (2021-2026)
7.2 Europe Checkpoint Inhibitors for Treating Cancer Sales by Checkpoint Target (2021-2026)
7.3 Europe Checkpoint Inhibitors for Treating Cancer Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Checkpoint Inhibitors for Treating Cancer by Country
8.1.1 Middle East & Africa Checkpoint Inhibitors for Treating Cancer Sales by Country (2021-2026)
8.1.2 Middle East & Africa Checkpoint Inhibitors for Treating Cancer Revenue by Country (2021-2026)
8.2 Middle East & Africa Checkpoint Inhibitors for Treating Cancer Sales by Checkpoint Target (2021-2026)
8.3 Middle East & Africa Checkpoint Inhibitors for Treating Cancer Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Checkpoint Inhibitors for Treating Cancer
10.3 Manufacturing Process Analysis of Checkpoint Inhibitors for Treating Cancer
10.4 Industry Chain Structure of Checkpoint Inhibitors for Treating Cancer
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Checkpoint Inhibitors for Treating Cancer Distributors
11.3 Checkpoint Inhibitors for Treating Cancer Customer
12 WORLD FORECAST REVIEW FOR CHECKPOINT INHIBITORS FOR TREATING CANCER BY GEOGRAPHIC REGION
12.1 Global Checkpoint Inhibitors for Treating Cancer Market Size Forecast by Region
12.1.1 Global Checkpoint Inhibitors for Treating Cancer Forecast by Region (2027-2032)
12.1.2 Global Checkpoint Inhibitors for Treating Cancer Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Checkpoint Inhibitors for Treating Cancer Forecast by Checkpoint Target (2027-2032)
12.7 Global Checkpoint Inhibitors for Treating Cancer Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Merck & Co.
13.1.1 Merck & Co. Company Information
13.1.2 Merck & Co. Checkpoint Inhibitors for Treating Cancer Product Portfolios and Specifications
13.1.3 Merck & Co. Checkpoint Inhibitors for Treating Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Merck & Co. Main Business Overview
13.1.5 Merck & Co. Latest Developments
13.2 Bristol Myers Squibb
13.2.1 Bristol Myers Squibb Company Information
13.2.2 Bristol Myers Squibb Checkpoint Inhibitors for Treating Cancer Product Portfolios and Specifications
13.2.3 Bristol Myers Squibb Checkpoint Inhibitors for Treating Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Bristol Myers Squibb Main Business Overview
13.2.5 Bristol Myers Squibb Latest Developments
13.3 AstraZeneca
13.3.1 AstraZeneca Company Information
13.3.2 AstraZeneca Checkpoint Inhibitors for Treating Cancer Product Portfolios and Specifications
13.3.3 AstraZeneca Checkpoint Inhibitors for Treating Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 AstraZeneca Main Business Overview
13.3.5 AstraZeneca Latest Developments
13.4 Roche
13.4.1 Roche Company Information
13.4.2 Roche Checkpoint Inhibitors for Treating Cancer Product Portfolios and Specifications
13.4.3 Roche Checkpoint Inhibitors for Treating Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Roche Main Business Overview
13.4.5 Roche Latest Developments
13.5 Regeneron Pharmaceuticals
13.5.1 Regeneron Pharmaceuticals Company Information
13.5.2 Regeneron Pharmaceuticals Checkpoint Inhibitors for Treating Cancer Product Portfolios and Specifications
13.5.3 Regeneron Pharmaceuticals Checkpoint Inhibitors for Treating Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Regeneron Pharmaceuticals Main Business Overview
13.5.5 Regeneron Pharmaceuticals Latest Developments
13.6 GSK
13.6.1 GSK Company Information
13.6.2 GSK Checkpoint Inhibitors for Treating Cancer Product Portfolios and Specifications
13.6.3 GSK Checkpoint Inhibitors for Treating Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 GSK Main Business Overview
13.6.5 GSK Latest Developments
13.7 Ono Pharmaceutical
13.7.1 Ono Pharmaceutical Company Information
13.7.2 Ono Pharmaceutical Checkpoint Inhibitors for Treating Cancer Product Portfolios and Specifications
13.7.3 Ono Pharmaceutical Checkpoint Inhibitors for Treating Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Ono Pharmaceutical Main Business Overview
13.7.5 Ono Pharmaceutical Latest Developments
13.8 BeOne Medicines
13.8.1 BeOne Medicines Company Information
13.8.2 BeOne Medicines Checkpoint Inhibitors for Treating Cancer Product Portfolios and Specifications
13.8.3 BeOne Medicines Checkpoint Inhibitors for Treating Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 BeOne Medicines Main Business Overview
13.8.5 BeOne Medicines Latest Developments
13.9 Merck KGaA
13.9.1 Merck KGaA Company Information
13.9.2 Merck KGaA Checkpoint Inhibitors for Treating Cancer Product Portfolios and Specifications
13.9.3 Merck KGaA Checkpoint Inhibitors for Treating Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Merck KGaA Main Business Overview
13.9.5 Merck KGaA Latest Developments
13.10 Innovent Biologics
13.10.1 Innovent Biologics Company Information
13.10.2 Innovent Biologics Checkpoint Inhibitors for Treating Cancer Product Portfolios and Specifications
13.10.3 Innovent Biologics Checkpoint Inhibitors for Treating Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Innovent Biologics Main Business Overview
13.10.5 Innovent Biologics Latest Developments
13.11 Jiangsu Hengrui Pharmaceuticals
13.11.1 Jiangsu Hengrui Pharmaceuticals Company Information
13.11.2 Jiangsu Hengrui Pharmaceuticals Checkpoint Inhibitors for Treating Cancer Product Portfolios and Specifications
13.11.3 Jiangsu Hengrui Pharmaceuticals Checkpoint Inhibitors for Treating Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 Jiangsu Hengrui Pharmaceuticals Main Business Overview
13.11.5 Jiangsu Hengrui Pharmaceuticals Latest Developments
13.12 Shanghai Junshi Biosciences
13.12.1 Shanghai Junshi Biosciences Company Information
13.12.2 Shanghai Junshi Biosciences Checkpoint Inhibitors for Treating Cancer Product Portfolios and Specifications
13.12.3 Shanghai Junshi Biosciences Checkpoint Inhibitors for Treating Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 Shanghai Junshi Biosciences Main Business Overview
13.12.5 Shanghai Junshi Biosciences Latest Developments
13.13 Akeso
13.13.1 Akeso Company Information
13.13.2 Akeso Checkpoint Inhibitors for Treating Cancer Product Portfolios and Specifications
13.13.3 Akeso Checkpoint Inhibitors for Treating Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
13.13.4 Akeso Main Business Overview
13.13.5 Akeso Latest Developments
13.14 Shanghai Henlius Biotech
13.14.1 Shanghai Henlius Biotech Company Information
13.14.2 Shanghai Henlius Biotech Checkpoint Inhibitors for Treating Cancer Product Portfolios and Specifications
13.14.3 Shanghai Henlius Biotech Checkpoint Inhibitors for Treating Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
13.14.4 Shanghai Henlius Biotech Main Business Overview
13.14.5 Shanghai Henlius Biotech Latest Developments
13.15 Incyte
13.15.1 Incyte Company Information
13.15.2 Incyte Checkpoint Inhibitors for Treating Cancer Product Portfolios and Specifications
13.15.3 Incyte Checkpoint Inhibitors for Treating Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
13.15.4 Incyte Main Business Overview
13.15.5 Incyte Latest Developments
13.16 Sino Biopharmaceutical
13.16.1 Sino Biopharmaceutical Company Information
13.16.2 Sino Biopharmaceutical Checkpoint Inhibitors for Treating Cancer Product Portfolios and Specifications
13.16.3 Sino Biopharmaceutical Checkpoint Inhibitors for Treating Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
13.16.4 Sino Biopharmaceutical Main Business Overview
13.16.5 Sino Biopharmaceutical Latest Developments
13.17 BIOCAD
13.17.1 BIOCAD Company Information
13.17.2 BIOCAD Checkpoint Inhibitors for Treating Cancer Product Portfolios and Specifications
13.17.3 BIOCAD Checkpoint Inhibitors for Treating Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
13.17.4 BIOCAD Main Business Overview
13.17.5 BIOCAD Latest Developments
13.18 Alphamab Oncology
13.18.1 Alphamab Oncology Company Information
13.18.2 Alphamab Oncology Checkpoint Inhibitors for Treating Cancer Product Portfolios and Specifications
13.18.3 Alphamab Oncology Checkpoint Inhibitors for Treating Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
13.18.4 Alphamab Oncology Main Business Overview
13.18.5 Alphamab Oncology Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Checkpoint Inhibitors for Treating Cancer Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Checkpoint Inhibitors for Treating Cancer Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of PD-1 Single-target Inhibitor
Table 4. Major Players of PD-L1 Single-target Inhibitor
Table 5. Major Players of CTLA-4 Single-target Inhibitor
Table 6. Major Players of PD-1/LAG-3 Combination
Table 7. Major Players of PD-1/CTLA-4 Dual Product
Table 8. Major Players of Other Checkpoint-containing Product
Table 9. Global Checkpoint Inhibitors for Treating Cancer Sales by Checkpoint Target (2021-2026) & (K Units)
Table 10. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Checkpoint Target (2021-2026)
Table 11. Global Checkpoint Inhibitors for Treating Cancer Revenue by Checkpoint Target (2021-2026) & ($ million)
Table 12. Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Checkpoint Target (2021-2026)
Table 13. Global Checkpoint Inhibitors for Treating Cancer Sale Price by Checkpoint Target (2021-2026) & (US$/Unit)
Table 14. Major Players of Monoclonal Antibody
Table 15. Major Players of Bispecific Antibody
Table 16. Major Players of Fixed-dose Antibody Combination
Table 17. Major Players of Antibody Enzyme Combination
Table 18. Global Checkpoint Inhibitors for Treating Cancer Sales by Molecular Format (2021-2026) & (K Units)
Table 19. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Molecular Format (2021-2026)
Table 20. Global Checkpoint Inhibitors for Treating Cancer Revenue by Molecular Format (2021-2026) & ($ million)
Table 21. Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Molecular Format (2021-2026)
Table 22. Global Checkpoint Inhibitors for Treating Cancer Sale Price by Molecular Format (2021-2026) & (US$/Unit)
Table 23. Major Players of Intravenous Liquid Concentrate
Table 24. Major Players of Intravenous Lyophilized Powder
Table 25. Major Players of Subcutaneous Ready-to-use Injection
Table 26. Global Checkpoint Inhibitors for Treating Cancer Sales by Dosage Form (2021-2026) & (K Units)
Table 27. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Dosage Form (2021-2026)
Table 28. Global Checkpoint Inhibitors for Treating Cancer Revenue by Dosage Form (2021-2026) & ($ million)
Table 29. Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Dosage Form (2021-2026)
Table 30. Global Checkpoint Inhibitors for Treating Cancer Sale Price by Dosage Form (2021-2026) & (US$/Unit)
Table 31. Global Checkpoint Inhibitors for Treating Cancer Sale by Application (2021-2026) & (K Units)
Table 32. Global Checkpoint Inhibitors for Treating Cancer Sale Market Share by Application (2021-2026)
Table 33. Global Checkpoint Inhibitors for Treating Cancer Revenue by Application (2021-2026) & ($ million)
Table 34. Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Application (2021-2026)
Table 35. Global Checkpoint Inhibitors for Treating Cancer Sale Price by Application (2021-2026) & (US$/Unit)
Table 36. Global Checkpoint Inhibitors for Treating Cancer Sales by Company (2021-2026) & (K Units)
Table 37. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Company (2021-2026)
Table 38. Global Checkpoint Inhibitors for Treating Cancer Revenue by Company (2021-2026) & ($ millions)
Table 39. Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Company (2021-2026)
Table 40. Global Checkpoint Inhibitors for Treating Cancer Sale Price by Company (2021-2026) & (US$/Unit)
Table 41. Key Manufacturers Checkpoint Inhibitors for Treating Cancer Producing Area Distribution and Sales Area
Table 42. Players Checkpoint Inhibitors for Treating Cancer Products Offered
Table 43. Checkpoint Inhibitors for Treating Cancer Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 44. New Products and Potential Entrants
Table 45. Market M&A Activity & Strategy
Table 46. Global Checkpoint Inhibitors for Treating Cancer Sales by Geographic Region (2021-2026) & (K Units)
Table 47. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share Geographic Region (2021-2026)
Table 48. Global Checkpoint Inhibitors for Treating Cancer Revenue by Geographic Region (2021-2026) & ($ millions)
Table 49. Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Geographic Region (2021-2026)
Table 50. Global Checkpoint Inhibitors for Treating Cancer Sales by Country/Region (2021-2026) & (K Units)
Table 51. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Country/Region (2021-2026)
Table 52. Global Checkpoint Inhibitors for Treating Cancer Revenue by Country/Region (2021-2026) & ($ millions)
Table 53. Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Country/Region (2021-2026)
Table 54. Americas Checkpoint Inhibitors for Treating Cancer Sales by Country (2021-2026) & (K Units)
Table 55. Americas Checkpoint Inhibitors for Treating Cancer Sales Market Share by Country (2021-2026)
Table 56. Americas Checkpoint Inhibitors for Treating Cancer Revenue by Country (2021-2026) & ($ millions)
Table 57. Americas Checkpoint Inhibitors for Treating Cancer Sales by Checkpoint Target (2021-2026) & (K Units)
Table 58. Americas Checkpoint Inhibitors for Treating Cancer Sales by Application (2021-2026) & (K Units)
Table 59. APAC Checkpoint Inhibitors for Treating Cancer Sales by Region (2021-2026) & (K Units)
Table 60. APAC Checkpoint Inhibitors for Treating Cancer Sales Market Share by Region (2021-2026)
Table 61. APAC Checkpoint Inhibitors for Treating Cancer Revenue by Region (2021-2026) & ($ millions)
Table 62. APAC Checkpoint Inhibitors for Treating Cancer Sales by Checkpoint Target (2021-2026) & (K Units)
Table 63. APAC Checkpoint Inhibitors for Treating Cancer Sales by Application (2021-2026) & (K Units)
Table 64. Europe Checkpoint Inhibitors for Treating Cancer Sales by Country (2021-2026) & (K Units)
Table 65. Europe Checkpoint Inhibitors for Treating Cancer Revenue by Country (2021-2026) & ($ millions)
Table 66. Europe Checkpoint Inhibitors for Treating Cancer Sales by Checkpoint Target (2021-2026) & (K Units)
Table 67. Europe Checkpoint Inhibitors for Treating Cancer Sales by Application (2021-2026) & (K Units)
Table 68. Middle East & Africa Checkpoint Inhibitors for Treating Cancer Sales by Country (2021-2026) & (K Units)
Table 69. Middle East & Africa Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Country (2021-2026)
Table 70. Middle East & Africa Checkpoint Inhibitors for Treating Cancer Sales by Checkpoint Target (2021-2026) & (K Units)
Table 71. Middle East & Africa Checkpoint Inhibitors for Treating Cancer Sales by Application (2021-2026) & (K Units)
Table 72. Key Market Drivers & Growth Opportunities of Checkpoint Inhibitors for Treating Cancer
Table 73. Key Market Challenges & Risks of Checkpoint Inhibitors for Treating Cancer
Table 74. Key Industry Trends of Checkpoint Inhibitors for Treating Cancer
Table 75. Checkpoint Inhibitors for Treating Cancer Raw Material
Table 76. Key Suppliers of Raw Materials
Table 77. Checkpoint Inhibitors for Treating Cancer Distributors List
Table 78. Checkpoint Inhibitors for Treating Cancer Customer List
Table 79. Global Checkpoint Inhibitors for Treating Cancer Sales Forecast by Region (2027-2032) & (K Units)
Table 80. Global Checkpoint Inhibitors for Treating Cancer Revenue Forecast by Region (2027-2032) & ($ millions)
Table 81. Americas Checkpoint Inhibitors for Treating Cancer Sales Forecast by Country (2027-2032) & (K Units)
Table 82. Americas Checkpoint Inhibitors for Treating Cancer Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 83. APAC Checkpoint Inhibitors for Treating Cancer Sales Forecast by Region (2027-2032) & (K Units)
Table 84. APAC Checkpoint Inhibitors for Treating Cancer Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 85. Europe Checkpoint Inhibitors for Treating Cancer Sales Forecast by Country (2027-2032) & (K Units)
Table 86. Europe Checkpoint Inhibitors for Treating Cancer Revenue Forecast by Country (2027-2032) & ($ millions)
Table 87. Middle East & Africa Checkpoint Inhibitors for Treating Cancer Sales Forecast by Country (2027-2032) & (K Units)
Table 88. Middle East & Africa Checkpoint Inhibitors for Treating Cancer Revenue Forecast by Country (2027-2032) & ($ millions)
Table 89. Global Checkpoint Inhibitors for Treating Cancer Sales Forecast by Checkpoint Target (2027-2032) & (K Units)
Table 90. Global Checkpoint Inhibitors for Treating Cancer Revenue Forecast by Checkpoint Target (2027-2032) & ($ millions)
Table 91. Global Checkpoint Inhibitors for Treating Cancer Sales Forecast by Application (2027-2032) & (K Units)
Table 92. Global Checkpoint Inhibitors for Treating Cancer Revenue Forecast by Application (2027-2032) & ($ millions)
Table 93. Merck & Co. Basic Information, Checkpoint Inhibitors for Treating Cancer Manufacturing Base, Sales Area and Its Competitors
Table 94. Merck & Co. Checkpoint Inhibitors for Treating Cancer Product Portfolios and Specifications
Table 95. Merck & Co. Checkpoint Inhibitors for Treating Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 96. Merck & Co. Main Business
Table 97. Merck & Co. Latest Developments
Table 98. Bristol Myers Squibb Basic Information, Checkpoint Inhibitors for Treating Cancer Manufacturing Base, Sales Area and Its Competitors
Table 99. Bristol Myers Squibb Checkpoint Inhibitors for Treating Cancer Product Portfolios and Specifications
Table 100. Bristol Myers Squibb Checkpoint Inhibitors for Treating Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 101. Bristol Myers Squibb Main Business
Table 102. Bristol Myers Squibb Latest Developments
Table 103. AstraZeneca Basic Information, Checkpoint Inhibitors for Treating Cancer Manufacturing Base, Sales Area and Its Competitors
Table 104. AstraZeneca Checkpoint Inhibitors for Treating Cancer Product Portfolios and Specifications
Table 105. AstraZeneca Checkpoint Inhibitors for Treating Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 106. AstraZeneca Main Business
Table 107. AstraZeneca Latest Developments
Table 108. Roche Basic Information, Checkpoint Inhibitors for Treating Cancer Manufacturing Base, Sales Area and Its Competitors
Table 109. Roche Checkpoint Inhibitors for Treating Cancer Product Portfolios and Specifications
Table 110. Roche Checkpoint Inhibitors for Treating Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 111. Roche Main Business
Table 112. Roche Latest Developments
Table 113. Regeneron Pharmaceuticals Basic Information, Checkpoint Inhibitors for Treating Cancer Manufacturing Base, Sales Area and Its Competitors
Table 114. Regeneron Pharmaceuticals Checkpoint Inhibitors for Treating Cancer Product Portfolios and Specifications
Table 115. Regeneron Pharmaceuticals Checkpoint Inhibitors for Treating Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 116. Regeneron Pharmaceuticals Main Business
Table 117. Regeneron Pharmaceuticals Latest Developments
Table 118. GSK Basic Information, Checkpoint Inhibitors for Treating Cancer Manufacturing Base, Sales Area and Its Competitors
Table 119. GSK Checkpoint Inhibitors for Treating Cancer Product Portfolios and Specifications
Table 120. GSK Checkpoint Inhibitors for Treating Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 121. GSK Main Business
Table 122. GSK Latest Developments
Table 123. Ono Pharmaceutical Basic Information, Checkpoint Inhibitors for Treating Cancer Manufacturing Base, Sales Area and Its Competitors
Table 124. Ono Pharmaceutical Checkpoint Inhibitors for Treating Cancer Product Portfolios and Specifications
Table 125. Ono Pharmaceutical Checkpoint Inhibitors for Treating Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 126. Ono Pharmaceutical Main Business
Table 127. Ono Pharmaceutical Latest Developments
Table 128. BeOne Medicines Basic Information, Checkpoint Inhibitors for Treating Cancer Manufacturing Base, Sales Area and Its Competitors
Table 129. BeOne Medicines Checkpoint Inhibitors for Treating Cancer Product Portfolios and Specifications
Table 130. BeOne Medicines Checkpoint Inhibitors for Treating Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 131. BeOne Medicines Main Business
Table 132. BeOne Medicines Latest Developments
Table 133. Merck KGaA Basic Information, Checkpoint Inhibitors for Treating Cancer Manufacturing Base, Sales Area and Its Competitors
Table 134. Merck KGaA Checkpoint Inhibitors for Treating Cancer Product Portfolios and Specifications
Table 135. Merck KGaA Checkpoint Inhibitors for Treating Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 136. Merck KGaA Main Business
Table 137. Merck KGaA Latest Developments
Table 138. Innovent Biologics Basic Information, Checkpoint Inhibitors for Treating Cancer Manufacturing Base, Sales Area and Its Competitors
Table 139. Innovent Biologics Checkpoint Inhibitors for Treating Cancer Product Portfolios and Specifications
Table 140. Innovent Biologics Checkpoint Inhibitors for Treating Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 141. Innovent Biologics Main Business
Table 142. Innovent Biologics Latest Developments
Table 143. Jiangsu Hengrui Pharmaceuticals Basic Information, Checkpoint Inhibitors for Treating Cancer Manufacturing Base, Sales Area and Its Competitors
Table 144. Jiangsu Hengrui Pharmaceuticals Checkpoint Inhibitors for Treating Cancer Product Portfolios and Specifications
Table 145. Jiangsu Hengrui Pharmaceuticals Checkpoint Inhibitors for Treating Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 146. Jiangsu Hengrui Pharmaceuticals Main Business
Table 147. Jiangsu Hengrui Pharmaceuticals Latest Developments
Table 148. Shanghai Junshi Biosciences Basic Information, Checkpoint Inhibitors for Treating Cancer Manufacturing Base, Sales Area and Its Competitors
Table 149. Shanghai Junshi Biosciences Checkpoint Inhibitors for Treating Cancer Product Portfolios and Specifications
Table 150. Shanghai Junshi Biosciences Checkpoint Inhibitors for Treating Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 151. Shanghai Junshi Biosciences Main Business
Table 152. Shanghai Junshi Biosciences Latest Developments
Table 153. Akeso Basic Information, Checkpoint Inhibitors for Treating Cancer Manufacturing Base, Sales Area and Its Competitors
Table 154. Akeso Checkpoint Inhibitors for Treating Cancer Product Portfolios and Specifications
Table 155. Akeso Checkpoint Inhibitors for Treating Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 156. Akeso Main Business
Table 157. Akeso Latest Developments
Table 158. Shanghai Henlius Biotech Basic Information, Checkpoint Inhibitors for Treating Cancer Manufacturing Base, Sales Area and Its Competitors
Table 159. Shanghai Henlius Biotech Checkpoint Inhibitors for Treating Cancer Product Portfolios and Specifications
Table 160. Shanghai Henlius Biotech Checkpoint Inhibitors for Treating Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 161. Shanghai Henlius Biotech Main Business
Table 162. Shanghai Henlius Biotech Latest Developments
Table 163. Incyte Basic Information, Checkpoint Inhibitors for Treating Cancer Manufacturing Base, Sales Area and Its Competitors
Table 164. Incyte Checkpoint Inhibitors for Treating Cancer Product Portfolios and Specifications
Table 165. Incyte Checkpoint Inhibitors for Treating Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 166. Incyte Main Business
Table 167. Incyte Latest Developments
Table 168. Sino Biopharmaceutical Basic Information, Checkpoint Inhibitors for Treating Cancer Manufacturing Base, Sales Area and Its Competitors
Table 169. Sino Biopharmaceutical Checkpoint Inhibitors for Treating Cancer Product Portfolios and Specifications
Table 170. Sino Biopharmaceutical Checkpoint Inhibitors for Treating Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 171. Sino Biopharmaceutical Main Business
Table 172. Sino Biopharmaceutical Latest Developments
Table 173. BIOCAD Basic Information, Checkpoint Inhibitors for Treating Cancer Manufacturing Base, Sales Area and Its Competitors
Table 174. BIOCAD Checkpoint Inhibitors for Treating Cancer Product Portfolios and Specifications
Table 175. BIOCAD Checkpoint Inhibitors for Treating Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 176. BIOCAD Main Business
Table 177. BIOCAD Latest Developments
Table 178. Alphamab Oncology Basic Information, Checkpoint Inhibitors for Treating Cancer Manufacturing Base, Sales Area and Its Competitors
Table 179. Alphamab Oncology Checkpoint Inhibitors for Treating Cancer Product Portfolios and Specifications
Table 180. Alphamab Oncology Checkpoint Inhibitors for Treating Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 181. Alphamab Oncology Main Business
Table 182. Alphamab Oncology Latest Developments
Table 1. Checkpoint Inhibitors for Treating Cancer Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Checkpoint Inhibitors for Treating Cancer Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of PD-1 Single-target Inhibitor
Table 4. Major Players of PD-L1 Single-target Inhibitor
Table 5. Major Players of CTLA-4 Single-target Inhibitor
Table 6. Major Players of PD-1/LAG-3 Combination
Table 7. Major Players of PD-1/CTLA-4 Dual Product
Table 8. Major Players of Other Checkpoint-containing Product
Table 9. Global Checkpoint Inhibitors for Treating Cancer Sales by Checkpoint Target (2021-2026) & (K Units)
Table 10. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Checkpoint Target (2021-2026)
Table 11. Global Checkpoint Inhibitors for Treating Cancer Revenue by Checkpoint Target (2021-2026) & ($ million)
Table 12. Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Checkpoint Target (2021-2026)
Table 13. Global Checkpoint Inhibitors for Treating Cancer Sale Price by Checkpoint Target (2021-2026) & (US$/Unit)
Table 14. Major Players of Monoclonal Antibody
Table 15. Major Players of Bispecific Antibody
Table 16. Major Players of Fixed-dose Antibody Combination
Table 17. Major Players of Antibody Enzyme Combination
Table 18. Global Checkpoint Inhibitors for Treating Cancer Sales by Molecular Format (2021-2026) & (K Units)
Table 19. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Molecular Format (2021-2026)
Table 20. Global Checkpoint Inhibitors for Treating Cancer Revenue by Molecular Format (2021-2026) & ($ million)
Table 21. Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Molecular Format (2021-2026)
Table 22. Global Checkpoint Inhibitors for Treating Cancer Sale Price by Molecular Format (2021-2026) & (US$/Unit)
Table 23. Major Players of Intravenous Liquid Concentrate
Table 24. Major Players of Intravenous Lyophilized Powder
Table 25. Major Players of Subcutaneous Ready-to-use Injection
Table 26. Global Checkpoint Inhibitors for Treating Cancer Sales by Dosage Form (2021-2026) & (K Units)
Table 27. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Dosage Form (2021-2026)
Table 28. Global Checkpoint Inhibitors for Treating Cancer Revenue by Dosage Form (2021-2026) & ($ million)
Table 29. Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Dosage Form (2021-2026)
Table 30. Global Checkpoint Inhibitors for Treating Cancer Sale Price by Dosage Form (2021-2026) & (US$/Unit)
Table 31. Global Checkpoint Inhibitors for Treating Cancer Sale by Application (2021-2026) & (K Units)
Table 32. Global Checkpoint Inhibitors for Treating Cancer Sale Market Share by Application (2021-2026)
Table 33. Global Checkpoint Inhibitors for Treating Cancer Revenue by Application (2021-2026) & ($ million)
Table 34. Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Application (2021-2026)
Table 35. Global Checkpoint Inhibitors for Treating Cancer Sale Price by Application (2021-2026) & (US$/Unit)
Table 36. Global Checkpoint Inhibitors for Treating Cancer Sales by Company (2021-2026) & (K Units)
Table 37. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Company (2021-2026)
Table 38. Global Checkpoint Inhibitors for Treating Cancer Revenue by Company (2021-2026) & ($ millions)
Table 39. Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Company (2021-2026)
Table 40. Global Checkpoint Inhibitors for Treating Cancer Sale Price by Company (2021-2026) & (US$/Unit)
Table 41. Key Manufacturers Checkpoint Inhibitors for Treating Cancer Producing Area Distribution and Sales Area
Table 42. Players Checkpoint Inhibitors for Treating Cancer Products Offered
Table 43. Checkpoint Inhibitors for Treating Cancer Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 44. New Products and Potential Entrants
Table 45. Market M&A Activity & Strategy
Table 46. Global Checkpoint Inhibitors for Treating Cancer Sales by Geographic Region (2021-2026) & (K Units)
Table 47. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share Geographic Region (2021-2026)
Table 48. Global Checkpoint Inhibitors for Treating Cancer Revenue by Geographic Region (2021-2026) & ($ millions)
Table 49. Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Geographic Region (2021-2026)
Table 50. Global Checkpoint Inhibitors for Treating Cancer Sales by Country/Region (2021-2026) & (K Units)
Table 51. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Country/Region (2021-2026)
Table 52. Global Checkpoint Inhibitors for Treating Cancer Revenue by Country/Region (2021-2026) & ($ millions)
Table 53. Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Country/Region (2021-2026)
Table 54. Americas Checkpoint Inhibitors for Treating Cancer Sales by Country (2021-2026) & (K Units)
Table 55. Americas Checkpoint Inhibitors for Treating Cancer Sales Market Share by Country (2021-2026)
Table 56. Americas Checkpoint Inhibitors for Treating Cancer Revenue by Country (2021-2026) & ($ millions)
Table 57. Americas Checkpoint Inhibitors for Treating Cancer Sales by Checkpoint Target (2021-2026) & (K Units)
Table 58. Americas Checkpoint Inhibitors for Treating Cancer Sales by Application (2021-2026) & (K Units)
Table 59. APAC Checkpoint Inhibitors for Treating Cancer Sales by Region (2021-2026) & (K Units)
Table 60. APAC Checkpoint Inhibitors for Treating Cancer Sales Market Share by Region (2021-2026)
Table 61. APAC Checkpoint Inhibitors for Treating Cancer Revenue by Region (2021-2026) & ($ millions)
Table 62. APAC Checkpoint Inhibitors for Treating Cancer Sales by Checkpoint Target (2021-2026) & (K Units)
Table 63. APAC Checkpoint Inhibitors for Treating Cancer Sales by Application (2021-2026) & (K Units)
Table 64. Europe Checkpoint Inhibitors for Treating Cancer Sales by Country (2021-2026) & (K Units)
Table 65. Europe Checkpoint Inhibitors for Treating Cancer Revenue by Country (2021-2026) & ($ millions)
Table 66. Europe Checkpoint Inhibitors for Treating Cancer Sales by Checkpoint Target (2021-2026) & (K Units)
Table 67. Europe Checkpoint Inhibitors for Treating Cancer Sales by Application (2021-2026) & (K Units)
Table 68. Middle East & Africa Checkpoint Inhibitors for Treating Cancer Sales by Country (2021-2026) & (K Units)
Table 69. Middle East & Africa Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Country (2021-2026)
Table 70. Middle East & Africa Checkpoint Inhibitors for Treating Cancer Sales by Checkpoint Target (2021-2026) & (K Units)
Table 71. Middle East & Africa Checkpoint Inhibitors for Treating Cancer Sales by Application (2021-2026) & (K Units)
Table 72. Key Market Drivers & Growth Opportunities of Checkpoint Inhibitors for Treating Cancer
Table 73. Key Market Challenges & Risks of Checkpoint Inhibitors for Treating Cancer
Table 74. Key Industry Trends of Checkpoint Inhibitors for Treating Cancer
Table 75. Checkpoint Inhibitors for Treating Cancer Raw Material
Table 76. Key Suppliers of Raw Materials
Table 77. Checkpoint Inhibitors for Treating Cancer Distributors List
Table 78. Checkpoint Inhibitors for Treating Cancer Customer List
Table 79. Global Checkpoint Inhibitors for Treating Cancer Sales Forecast by Region (2027-2032) & (K Units)
Table 80. Global Checkpoint Inhibitors for Treating Cancer Revenue Forecast by Region (2027-2032) & ($ millions)
Table 81. Americas Checkpoint Inhibitors for Treating Cancer Sales Forecast by Country (2027-2032) & (K Units)
Table 82. Americas Checkpoint Inhibitors for Treating Cancer Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 83. APAC Checkpoint Inhibitors for Treating Cancer Sales Forecast by Region (2027-2032) & (K Units)
Table 84. APAC Checkpoint Inhibitors for Treating Cancer Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 85. Europe Checkpoint Inhibitors for Treating Cancer Sales Forecast by Country (2027-2032) & (K Units)
Table 86. Europe Checkpoint Inhibitors for Treating Cancer Revenue Forecast by Country (2027-2032) & ($ millions)
Table 87. Middle East & Africa Checkpoint Inhibitors for Treating Cancer Sales Forecast by Country (2027-2032) & (K Units)
Table 88. Middle East & Africa Checkpoint Inhibitors for Treating Cancer Revenue Forecast by Country (2027-2032) & ($ millions)
Table 89. Global Checkpoint Inhibitors for Treating Cancer Sales Forecast by Checkpoint Target (2027-2032) & (K Units)
Table 90. Global Checkpoint Inhibitors for Treating Cancer Revenue Forecast by Checkpoint Target (2027-2032) & ($ millions)
Table 91. Global Checkpoint Inhibitors for Treating Cancer Sales Forecast by Application (2027-2032) & (K Units)
Table 92. Global Checkpoint Inhibitors for Treating Cancer Revenue Forecast by Application (2027-2032) & ($ millions)
Table 93. Merck & Co. Basic Information, Checkpoint Inhibitors for Treating Cancer Manufacturing Base, Sales Area and Its Competitors
Table 94. Merck & Co. Checkpoint Inhibitors for Treating Cancer Product Portfolios and Specifications
Table 95. Merck & Co. Checkpoint Inhibitors for Treating Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 96. Merck & Co. Main Business
Table 97. Merck & Co. Latest Developments
Table 98. Bristol Myers Squibb Basic Information, Checkpoint Inhibitors for Treating Cancer Manufacturing Base, Sales Area and Its Competitors
Table 99. Bristol Myers Squibb Checkpoint Inhibitors for Treating Cancer Product Portfolios and Specifications
Table 100. Bristol Myers Squibb Checkpoint Inhibitors for Treating Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 101. Bristol Myers Squibb Main Business
Table 102. Bristol Myers Squibb Latest Developments
Table 103. AstraZeneca Basic Information, Checkpoint Inhibitors for Treating Cancer Manufacturing Base, Sales Area and Its Competitors
Table 104. AstraZeneca Checkpoint Inhibitors for Treating Cancer Product Portfolios and Specifications
Table 105. AstraZeneca Checkpoint Inhibitors for Treating Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 106. AstraZeneca Main Business
Table 107. AstraZeneca Latest Developments
Table 108. Roche Basic Information, Checkpoint Inhibitors for Treating Cancer Manufacturing Base, Sales Area and Its Competitors
Table 109. Roche Checkpoint Inhibitors for Treating Cancer Product Portfolios and Specifications
Table 110. Roche Checkpoint Inhibitors for Treating Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 111. Roche Main Business
Table 112. Roche Latest Developments
Table 113. Regeneron Pharmaceuticals Basic Information, Checkpoint Inhibitors for Treating Cancer Manufacturing Base, Sales Area and Its Competitors
Table 114. Regeneron Pharmaceuticals Checkpoint Inhibitors for Treating Cancer Product Portfolios and Specifications
Table 115. Regeneron Pharmaceuticals Checkpoint Inhibitors for Treating Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 116. Regeneron Pharmaceuticals Main Business
Table 117. Regeneron Pharmaceuticals Latest Developments
Table 118. GSK Basic Information, Checkpoint Inhibitors for Treating Cancer Manufacturing Base, Sales Area and Its Competitors
Table 119. GSK Checkpoint Inhibitors for Treating Cancer Product Portfolios and Specifications
Table 120. GSK Checkpoint Inhibitors for Treating Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 121. GSK Main Business
Table 122. GSK Latest Developments
Table 123. Ono Pharmaceutical Basic Information, Checkpoint Inhibitors for Treating Cancer Manufacturing Base, Sales Area and Its Competitors
Table 124. Ono Pharmaceutical Checkpoint Inhibitors for Treating Cancer Product Portfolios and Specifications
Table 125. Ono Pharmaceutical Checkpoint Inhibitors for Treating Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 126. Ono Pharmaceutical Main Business
Table 127. Ono Pharmaceutical Latest Developments
Table 128. BeOne Medicines Basic Information, Checkpoint Inhibitors for Treating Cancer Manufacturing Base, Sales Area and Its Competitors
Table 129. BeOne Medicines Checkpoint Inhibitors for Treating Cancer Product Portfolios and Specifications
Table 130. BeOne Medicines Checkpoint Inhibitors for Treating Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 131. BeOne Medicines Main Business
Table 132. BeOne Medicines Latest Developments
Table 133. Merck KGaA Basic Information, Checkpoint Inhibitors for Treating Cancer Manufacturing Base, Sales Area and Its Competitors
Table 134. Merck KGaA Checkpoint Inhibitors for Treating Cancer Product Portfolios and Specifications
Table 135. Merck KGaA Checkpoint Inhibitors for Treating Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 136. Merck KGaA Main Business
Table 137. Merck KGaA Latest Developments
Table 138. Innovent Biologics Basic Information, Checkpoint Inhibitors for Treating Cancer Manufacturing Base, Sales Area and Its Competitors
Table 139. Innovent Biologics Checkpoint Inhibitors for Treating Cancer Product Portfolios and Specifications
Table 140. Innovent Biologics Checkpoint Inhibitors for Treating Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 141. Innovent Biologics Main Business
Table 142. Innovent Biologics Latest Developments
Table 143. Jiangsu Hengrui Pharmaceuticals Basic Information, Checkpoint Inhibitors for Treating Cancer Manufacturing Base, Sales Area and Its Competitors
Table 144. Jiangsu Hengrui Pharmaceuticals Checkpoint Inhibitors for Treating Cancer Product Portfolios and Specifications
Table 145. Jiangsu Hengrui Pharmaceuticals Checkpoint Inhibitors for Treating Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 146. Jiangsu Hengrui Pharmaceuticals Main Business
Table 147. Jiangsu Hengrui Pharmaceuticals Latest Developments
Table 148. Shanghai Junshi Biosciences Basic Information, Checkpoint Inhibitors for Treating Cancer Manufacturing Base, Sales Area and Its Competitors
Table 149. Shanghai Junshi Biosciences Checkpoint Inhibitors for Treating Cancer Product Portfolios and Specifications
Table 150. Shanghai Junshi Biosciences Checkpoint Inhibitors for Treating Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 151. Shanghai Junshi Biosciences Main Business
Table 152. Shanghai Junshi Biosciences Latest Developments
Table 153. Akeso Basic Information, Checkpoint Inhibitors for Treating Cancer Manufacturing Base, Sales Area and Its Competitors
Table 154. Akeso Checkpoint Inhibitors for Treating Cancer Product Portfolios and Specifications
Table 155. Akeso Checkpoint Inhibitors for Treating Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 156. Akeso Main Business
Table 157. Akeso Latest Developments
Table 158. Shanghai Henlius Biotech Basic Information, Checkpoint Inhibitors for Treating Cancer Manufacturing Base, Sales Area and Its Competitors
Table 159. Shanghai Henlius Biotech Checkpoint Inhibitors for Treating Cancer Product Portfolios and Specifications
Table 160. Shanghai Henlius Biotech Checkpoint Inhibitors for Treating Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 161. Shanghai Henlius Biotech Main Business
Table 162. Shanghai Henlius Biotech Latest Developments
Table 163. Incyte Basic Information, Checkpoint Inhibitors for Treating Cancer Manufacturing Base, Sales Area and Its Competitors
Table 164. Incyte Checkpoint Inhibitors for Treating Cancer Product Portfolios and Specifications
Table 165. Incyte Checkpoint Inhibitors for Treating Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 166. Incyte Main Business
Table 167. Incyte Latest Developments
Table 168. Sino Biopharmaceutical Basic Information, Checkpoint Inhibitors for Treating Cancer Manufacturing Base, Sales Area and Its Competitors
Table 169. Sino Biopharmaceutical Checkpoint Inhibitors for Treating Cancer Product Portfolios and Specifications
Table 170. Sino Biopharmaceutical Checkpoint Inhibitors for Treating Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 171. Sino Biopharmaceutical Main Business
Table 172. Sino Biopharmaceutical Latest Developments
Table 173. BIOCAD Basic Information, Checkpoint Inhibitors for Treating Cancer Manufacturing Base, Sales Area and Its Competitors
Table 174. BIOCAD Checkpoint Inhibitors for Treating Cancer Product Portfolios and Specifications
Table 175. BIOCAD Checkpoint Inhibitors for Treating Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 176. BIOCAD Main Business
Table 177. BIOCAD Latest Developments
Table 178. Alphamab Oncology Basic Information, Checkpoint Inhibitors for Treating Cancer Manufacturing Base, Sales Area and Its Competitors
Table 179. Alphamab Oncology Checkpoint Inhibitors for Treating Cancer Product Portfolios and Specifications
Table 180. Alphamab Oncology Checkpoint Inhibitors for Treating Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 181. Alphamab Oncology Main Business
Table 182. Alphamab Oncology Latest Developments
LIST OF FIGURES
Figure 1. Picture of Checkpoint Inhibitors for Treating Cancer
Figure 2. Checkpoint Inhibitors for Treating Cancer Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Checkpoint Inhibitors for Treating Cancer Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Checkpoint Inhibitors for Treating Cancer Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Checkpoint Inhibitors for Treating Cancer Sales Market Share by Country/Region (2025)
Figure 10. Checkpoint Inhibitors for Treating Cancer Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of PD-1 Single-target Inhibitor
Figure 12. Product Picture of PD-L1 Single-target Inhibitor
Figure 13. Product Picture of CTLA-4 Single-target Inhibitor
Figure 14. Product Picture of PD-1/LAG-3 Combination
Figure 15. Product Picture of PD-1/CTLA-4 Dual Product
Figure 16. Product Picture of Other Checkpoint-containing Product
Figure 17. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Checkpoint Target in 2026
Figure 18. Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Checkpoint Target (2021-2026)
Figure 19. Product Picture of Monoclonal Antibody
Figure 20. Product Picture of Bispecific Antibody
Figure 21. Product Picture of Fixed-dose Antibody Combination
Figure 22. Product Picture of Antibody Enzyme Combination
Figure 23. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Molecular Format in 2026
Figure 24. Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Molecular Format (2021-2026)
Figure 25. Product Picture of Intravenous Liquid Concentrate
Figure 26. Product Picture of Intravenous Lyophilized Powder
Figure 27. Product Picture of Subcutaneous Ready-to-use Injection
Figure 28. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Dosage Form in 2026
Figure 29. Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Dosage Form (2021-2026)
Figure 30. Checkpoint Inhibitors for Treating Cancer Consumed in Lung Cancer
Figure 31. Global Checkpoint Inhibitors for Treating Cancer Market: Lung Cancer (2021-2026) & (K Units)
Figure 32. Checkpoint Inhibitors for Treating Cancer Consumed in Gastrointestinal Cancer
Figure 33. Global Checkpoint Inhibitors for Treating Cancer Market: Gastrointestinal Cancer (2021-2026) & (K Units)
Figure 34. Checkpoint Inhibitors for Treating Cancer Consumed in Genitourinary Cancer
Figure 35. Global Checkpoint Inhibitors for Treating Cancer Market: Genitourinary Cancer (2021-2026) & (K Units)
Figure 36. Checkpoint Inhibitors for Treating Cancer Consumed in Hepatobiliary Cancer
Figure 37. Global Checkpoint Inhibitors for Treating Cancer Market: Hepatobiliary Cancer (2021-2026) & (K Units)
Figure 38. Checkpoint Inhibitors for Treating Cancer Consumed in Gynecologic Cancer
Figure 39. Global Checkpoint Inhibitors for Treating Cancer Market: Gynecologic Cancer (2021-2026) & (K Units)
Figure 40. Checkpoint Inhibitors for Treating Cancer Consumed in Skin Cancer
Figure 41. Global Checkpoint Inhibitors for Treating Cancer Market: Skin Cancer (2021-2026) & (K Units)
Figure 42. Checkpoint Inhibitors for Treating Cancer Consumed in Breast Cancer
Figure 43. Global Checkpoint Inhibitors for Treating Cancer Market: Breast Cancer (2021-2026) & (K Units)
Figure 44. Checkpoint Inhibitors for Treating Cancer Consumed in Head and Neck Cancer
Figure 45. Global Checkpoint Inhibitors for Treating Cancer Market: Head and Neck Cancer (2021-2026) & (K Units)
Figure 46. Checkpoint Inhibitors for Treating Cancer Consumed in Hematologic Malignancy
Figure 47. Global Checkpoint Inhibitors for Treating Cancer Market: Hematologic Malignancy (2021-2026) & (K Units)
Figure 48. Global Checkpoint Inhibitors for Treating Cancer Sale Market Share by Application (2025)
Figure 49. Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Application in 2025
Figure 50. Checkpoint Inhibitors for Treating Cancer Sales by Company in 2025 (K Units)
Figure 51. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Company in 2025
Figure 52. Checkpoint Inhibitors for Treating Cancer Revenue by Company in 2025 ($ millions)
Figure 53. Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Company in 2025
Figure 54. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Geographic Region (2021-2026)
Figure 55. Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Geographic Region in 2025
Figure 56. Americas Checkpoint Inhibitors for Treating Cancer Sales 2021-2026 (K Units)
Figure 57. Americas Checkpoint Inhibitors for Treating Cancer Revenue 2021-2026 ($ millions)
Figure 58. APAC Checkpoint Inhibitors for Treating Cancer Sales 2021-2026 (K Units)
Figure 59. APAC Checkpoint Inhibitors for Treating Cancer Revenue 2021-2026 ($ millions)
Figure 60. Europe Checkpoint Inhibitors for Treating Cancer Sales 2021-2026 (K Units)
Figure 61. Europe Checkpoint Inhibitors for Treating Cancer Revenue 2021-2026 ($ millions)
Figure 62. Middle East & Africa Checkpoint Inhibitors for Treating Cancer Sales 2021-2026 (K Units)
Figure 63. Middle East & Africa Checkpoint Inhibitors for Treating Cancer Revenue 2021-2026 ($ millions)
Figure 64. Americas Checkpoint Inhibitors for Treating Cancer Sales Market Share by Country in 2025
Figure 65. Americas Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Country (2021-2026)
Figure 66. Americas Checkpoint Inhibitors for Treating Cancer Sales Market Share by Checkpoint Target (2021-2026)
Figure 67. Americas Checkpoint Inhibitors for Treating Cancer Sales Market Share by Application (2021-2026)
Figure 68. United States Checkpoint Inhibitors for Treating Cancer Revenue Growth 2021-2026 ($ millions)
Figure 69. Canada Checkpoint Inhibitors for Treating Cancer Revenue Growth 2021-2026 ($ millions)
Figure 70. Mexico Checkpoint Inhibitors for Treating Cancer Revenue Growth 2021-2026 ($ millions)
Figure 71. Brazil Checkpoint Inhibitors for Treating Cancer Revenue Growth 2021-2026 ($ millions)
Figure 72. APAC Checkpoint Inhibitors for Treating Cancer Sales Market Share by Region in 2025
Figure 73. APAC Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Region (2021-2026)
Figure 74. APAC Checkpoint Inhibitors for Treating Cancer Sales Market Share by Checkpoint Target (2021-2026)
Figure 75. APAC Checkpoint Inhibitors for Treating Cancer Sales Market Share by Application (2021-2026)
Figure 76. China Checkpoint Inhibitors for Treating Cancer Revenue Growth 2021-2026 ($ millions)
Figure 77. Japan Checkpoint Inhibitors for Treating Cancer Revenue Growth 2021-2026 ($ millions)
Figure 78. South Korea Checkpoint Inhibitors for Treating Cancer Revenue Growth 2021-2026 ($ millions)
Figure 79. Southeast Asia Checkpoint Inhibitors for Treating Cancer Revenue Growth 2021-2026 ($ millions)
Figure 80. India Checkpoint Inhibitors for Treating Cancer Revenue Growth 2021-2026 ($ millions)
Figure 81. Australia Checkpoint Inhibitors for Treating Cancer Revenue Growth 2021-2026 ($ millions)
Figure 82. China Taiwan Checkpoint Inhibitors for Treating Cancer Revenue Growth 2021-2026 ($ millions)
Figure 83. Europe Checkpoint Inhibitors for Treating Cancer Sales Market Share by Country in 2025
Figure 84. Europe Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Country (2021-2026)
Figure 85. Europe Checkpoint Inhibitors for Treating Cancer Sales Market Share by Checkpoint Target (2021-2026)
Figure 86. Europe Checkpoint Inhibitors for Treating Cancer Sales Market Share by Application (2021-2026)
Figure 87. Germany Checkpoint Inhibitors for Treating Cancer Revenue Growth 2021-2026 ($ millions)
Figure 88. France Checkpoint Inhibitors for Treating Cancer Revenue Growth 2021-2026 ($ millions)
Figure 89. UK Checkpoint Inhibitors for Treating Cancer Revenue Growth 2021-2026 ($ millions)
Figure 90. Italy Checkpoint Inhibitors for Treating Cancer Revenue Growth 2021-2026 ($ millions)
Figure 91. Russia Checkpoint Inhibitors for Treating Cancer Revenue Growth 2021-2026 ($ millions)
Figure 92. Middle East & Africa Checkpoint Inhibitors for Treating Cancer Sales Market Share by Country (2021-2026)
Figure 93. Middle East & Africa Checkpoint Inhibitors for Treating Cancer Sales Market Share by Checkpoint Target (2021-2026)
Figure 94. Middle East & Africa Checkpoint Inhibitors for Treating Cancer Sales Market Share by Application (2021-2026)
Figure 95. Egypt Checkpoint Inhibitors for Treating Cancer Revenue Growth 2021-2026 ($ millions)
Figure 96. South Africa Checkpoint Inhibitors for Treating Cancer Revenue Growth 2021-2026 ($ millions)
Figure 97. Israel Checkpoint Inhibitors for Treating Cancer Revenue Growth 2021-2026 ($ millions)
Figure 98. Turkey Checkpoint Inhibitors for Treating Cancer Revenue Growth 2021-2026 ($ millions)
Figure 99. GCC Countries Checkpoint Inhibitors for Treating Cancer Revenue Growth 2021-2026 ($ millions)
Figure 100. Manufacturing Cost Structure Analysis of Checkpoint Inhibitors for Treating Cancer in 2026
Figure 101. Manufacturing Process Analysis of Checkpoint Inhibitors for Treating Cancer
Figure 102. Industry Chain Structure of Checkpoint Inhibitors for Treating Cancer
Figure 103. Channels of Distribution
Figure 104. Global Checkpoint Inhibitors for Treating Cancer Sales Market Forecast by Region (2027-2032)
Figure 105. Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share Forecast by Region (2027-2032)
Figure 106. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share Forecast by Checkpoint Target (2027-2032)
Figure 107. Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share Forecast by Checkpoint Target (2027-2032)
Figure 108. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share Forecast by Application (2027-2032)
Figure 109. Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share Forecast by Application (2027-2032)
Figure 1. Picture of Checkpoint Inhibitors for Treating Cancer
Figure 2. Checkpoint Inhibitors for Treating Cancer Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Checkpoint Inhibitors for Treating Cancer Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Checkpoint Inhibitors for Treating Cancer Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Checkpoint Inhibitors for Treating Cancer Sales Market Share by Country/Region (2025)
Figure 10. Checkpoint Inhibitors for Treating Cancer Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of PD-1 Single-target Inhibitor
Figure 12. Product Picture of PD-L1 Single-target Inhibitor
Figure 13. Product Picture of CTLA-4 Single-target Inhibitor
Figure 14. Product Picture of PD-1/LAG-3 Combination
Figure 15. Product Picture of PD-1/CTLA-4 Dual Product
Figure 16. Product Picture of Other Checkpoint-containing Product
Figure 17. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Checkpoint Target in 2026
Figure 18. Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Checkpoint Target (2021-2026)
Figure 19. Product Picture of Monoclonal Antibody
Figure 20. Product Picture of Bispecific Antibody
Figure 21. Product Picture of Fixed-dose Antibody Combination
Figure 22. Product Picture of Antibody Enzyme Combination
Figure 23. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Molecular Format in 2026
Figure 24. Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Molecular Format (2021-2026)
Figure 25. Product Picture of Intravenous Liquid Concentrate
Figure 26. Product Picture of Intravenous Lyophilized Powder
Figure 27. Product Picture of Subcutaneous Ready-to-use Injection
Figure 28. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Dosage Form in 2026
Figure 29. Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Dosage Form (2021-2026)
Figure 30. Checkpoint Inhibitors for Treating Cancer Consumed in Lung Cancer
Figure 31. Global Checkpoint Inhibitors for Treating Cancer Market: Lung Cancer (2021-2026) & (K Units)
Figure 32. Checkpoint Inhibitors for Treating Cancer Consumed in Gastrointestinal Cancer
Figure 33. Global Checkpoint Inhibitors for Treating Cancer Market: Gastrointestinal Cancer (2021-2026) & (K Units)
Figure 34. Checkpoint Inhibitors for Treating Cancer Consumed in Genitourinary Cancer
Figure 35. Global Checkpoint Inhibitors for Treating Cancer Market: Genitourinary Cancer (2021-2026) & (K Units)
Figure 36. Checkpoint Inhibitors for Treating Cancer Consumed in Hepatobiliary Cancer
Figure 37. Global Checkpoint Inhibitors for Treating Cancer Market: Hepatobiliary Cancer (2021-2026) & (K Units)
Figure 38. Checkpoint Inhibitors for Treating Cancer Consumed in Gynecologic Cancer
Figure 39. Global Checkpoint Inhibitors for Treating Cancer Market: Gynecologic Cancer (2021-2026) & (K Units)
Figure 40. Checkpoint Inhibitors for Treating Cancer Consumed in Skin Cancer
Figure 41. Global Checkpoint Inhibitors for Treating Cancer Market: Skin Cancer (2021-2026) & (K Units)
Figure 42. Checkpoint Inhibitors for Treating Cancer Consumed in Breast Cancer
Figure 43. Global Checkpoint Inhibitors for Treating Cancer Market: Breast Cancer (2021-2026) & (K Units)
Figure 44. Checkpoint Inhibitors for Treating Cancer Consumed in Head and Neck Cancer
Figure 45. Global Checkpoint Inhibitors for Treating Cancer Market: Head and Neck Cancer (2021-2026) & (K Units)
Figure 46. Checkpoint Inhibitors for Treating Cancer Consumed in Hematologic Malignancy
Figure 47. Global Checkpoint Inhibitors for Treating Cancer Market: Hematologic Malignancy (2021-2026) & (K Units)
Figure 48. Global Checkpoint Inhibitors for Treating Cancer Sale Market Share by Application (2025)
Figure 49. Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Application in 2025
Figure 50. Checkpoint Inhibitors for Treating Cancer Sales by Company in 2025 (K Units)
Figure 51. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Company in 2025
Figure 52. Checkpoint Inhibitors for Treating Cancer Revenue by Company in 2025 ($ millions)
Figure 53. Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Company in 2025
Figure 54. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Geographic Region (2021-2026)
Figure 55. Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Geographic Region in 2025
Figure 56. Americas Checkpoint Inhibitors for Treating Cancer Sales 2021-2026 (K Units)
Figure 57. Americas Checkpoint Inhibitors for Treating Cancer Revenue 2021-2026 ($ millions)
Figure 58. APAC Checkpoint Inhibitors for Treating Cancer Sales 2021-2026 (K Units)
Figure 59. APAC Checkpoint Inhibitors for Treating Cancer Revenue 2021-2026 ($ millions)
Figure 60. Europe Checkpoint Inhibitors for Treating Cancer Sales 2021-2026 (K Units)
Figure 61. Europe Checkpoint Inhibitors for Treating Cancer Revenue 2021-2026 ($ millions)
Figure 62. Middle East & Africa Checkpoint Inhibitors for Treating Cancer Sales 2021-2026 (K Units)
Figure 63. Middle East & Africa Checkpoint Inhibitors for Treating Cancer Revenue 2021-2026 ($ millions)
Figure 64. Americas Checkpoint Inhibitors for Treating Cancer Sales Market Share by Country in 2025
Figure 65. Americas Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Country (2021-2026)
Figure 66. Americas Checkpoint Inhibitors for Treating Cancer Sales Market Share by Checkpoint Target (2021-2026)
Figure 67. Americas Checkpoint Inhibitors for Treating Cancer Sales Market Share by Application (2021-2026)
Figure 68. United States Checkpoint Inhibitors for Treating Cancer Revenue Growth 2021-2026 ($ millions)
Figure 69. Canada Checkpoint Inhibitors for Treating Cancer Revenue Growth 2021-2026 ($ millions)
Figure 70. Mexico Checkpoint Inhibitors for Treating Cancer Revenue Growth 2021-2026 ($ millions)
Figure 71. Brazil Checkpoint Inhibitors for Treating Cancer Revenue Growth 2021-2026 ($ millions)
Figure 72. APAC Checkpoint Inhibitors for Treating Cancer Sales Market Share by Region in 2025
Figure 73. APAC Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Region (2021-2026)
Figure 74. APAC Checkpoint Inhibitors for Treating Cancer Sales Market Share by Checkpoint Target (2021-2026)
Figure 75. APAC Checkpoint Inhibitors for Treating Cancer Sales Market Share by Application (2021-2026)
Figure 76. China Checkpoint Inhibitors for Treating Cancer Revenue Growth 2021-2026 ($ millions)
Figure 77. Japan Checkpoint Inhibitors for Treating Cancer Revenue Growth 2021-2026 ($ millions)
Figure 78. South Korea Checkpoint Inhibitors for Treating Cancer Revenue Growth 2021-2026 ($ millions)
Figure 79. Southeast Asia Checkpoint Inhibitors for Treating Cancer Revenue Growth 2021-2026 ($ millions)
Figure 80. India Checkpoint Inhibitors for Treating Cancer Revenue Growth 2021-2026 ($ millions)
Figure 81. Australia Checkpoint Inhibitors for Treating Cancer Revenue Growth 2021-2026 ($ millions)
Figure 82. China Taiwan Checkpoint Inhibitors for Treating Cancer Revenue Growth 2021-2026 ($ millions)
Figure 83. Europe Checkpoint Inhibitors for Treating Cancer Sales Market Share by Country in 2025
Figure 84. Europe Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Country (2021-2026)
Figure 85. Europe Checkpoint Inhibitors for Treating Cancer Sales Market Share by Checkpoint Target (2021-2026)
Figure 86. Europe Checkpoint Inhibitors for Treating Cancer Sales Market Share by Application (2021-2026)
Figure 87. Germany Checkpoint Inhibitors for Treating Cancer Revenue Growth 2021-2026 ($ millions)
Figure 88. France Checkpoint Inhibitors for Treating Cancer Revenue Growth 2021-2026 ($ millions)
Figure 89. UK Checkpoint Inhibitors for Treating Cancer Revenue Growth 2021-2026 ($ millions)
Figure 90. Italy Checkpoint Inhibitors for Treating Cancer Revenue Growth 2021-2026 ($ millions)
Figure 91. Russia Checkpoint Inhibitors for Treating Cancer Revenue Growth 2021-2026 ($ millions)
Figure 92. Middle East & Africa Checkpoint Inhibitors for Treating Cancer Sales Market Share by Country (2021-2026)
Figure 93. Middle East & Africa Checkpoint Inhibitors for Treating Cancer Sales Market Share by Checkpoint Target (2021-2026)
Figure 94. Middle East & Africa Checkpoint Inhibitors for Treating Cancer Sales Market Share by Application (2021-2026)
Figure 95. Egypt Checkpoint Inhibitors for Treating Cancer Revenue Growth 2021-2026 ($ millions)
Figure 96. South Africa Checkpoint Inhibitors for Treating Cancer Revenue Growth 2021-2026 ($ millions)
Figure 97. Israel Checkpoint Inhibitors for Treating Cancer Revenue Growth 2021-2026 ($ millions)
Figure 98. Turkey Checkpoint Inhibitors for Treating Cancer Revenue Growth 2021-2026 ($ millions)
Figure 99. GCC Countries Checkpoint Inhibitors for Treating Cancer Revenue Growth 2021-2026 ($ millions)
Figure 100. Manufacturing Cost Structure Analysis of Checkpoint Inhibitors for Treating Cancer in 2026
Figure 101. Manufacturing Process Analysis of Checkpoint Inhibitors for Treating Cancer
Figure 102. Industry Chain Structure of Checkpoint Inhibitors for Treating Cancer
Figure 103. Channels of Distribution
Figure 104. Global Checkpoint Inhibitors for Treating Cancer Sales Market Forecast by Region (2027-2032)
Figure 105. Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share Forecast by Region (2027-2032)
Figure 106. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share Forecast by Checkpoint Target (2027-2032)
Figure 107. Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share Forecast by Checkpoint Target (2027-2032)
Figure 108. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share Forecast by Application (2027-2032)
Figure 109. Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share Forecast by Application (2027-2032)
